Whether obesity influences content and functional capacity of skeletal muscle mitochondria (MITO) remains unresolved. In this study, biopsies of vastus lateralis from lean and obese human subjects were used to isolate subsarcolemmal (SS) and intermyofibrillar (IMF) MITO. IMF MITO were liberated using a protease. The SS and IMF were pelleted separately, using differential centrifugation. Skeletal muscle from obese subjects gave higher MITO protein yield, per g wet muscle vs. skeletal muscle from lean subjects in the SS but not in the IMF. There was a trend for higher isolated yields of citrate synthase (CS) activity, a marker for MITO content, in the muscle of obese subjects vs. lean subjects in SS, but not in IMF MITO. O 2 consumption ( J O ) and ATP production rates measured with NAD‐linked substrates (malate+pyruvate+glutamate), were not different in obese vs. lean in either SS or IMF MITO expressed either per mg MITO protein or per unit CS activity. The similarities in MITO function observed in SS and IMF from both lean and obese human muscle, suggests comparable functional capacity per unit MITO, regardless of the location within the myocyte, or whether the MITO reside in skeletal muscle from lean or obese subjects. However, higher total yield of both protein and CS activities in the SS MITO from the muscle of obese subjects, point to the possibility for greater content of SS MITO in muscle of obese individuals. This conclusion must be qualified; these results may be due to a greater fractional yield of MITO during the isolation procedure of skeletal muscle from obese subjects.
L‐[2,3,3,4,5,5,5,6,6,6‐2H10]leucine improves accuracy of muscle protein synthesis determinations when using blood amino acid enrichment as the precursor pool (258.8)
The amino acid enrichment in blood (E b ) is often used in clinically relevant stable isotope studies to calculate muscle protein fractional synthesis rates (FSR), but it underestimates the FSR compared to methods using intracellular enrichment in muscle (E i ). We compared the FSR calculated with intravenous infusion of the novel tracer L‐[2,3,3,4,5,5,5,6,6,6‐ 2 H 10 ]leucine ([ 2 H 10 ]leu) to infusion of the traditional tracer L‐[ 13 C 6 ]phenylalanine ([ 13 C 6 ]phe) using E b and E i . Because [ 2 H 10 ]leu is intracellularly metabolized to [ 2 H 9 ]leu prior to reentry into the blood, we hypothesize that using [ 2 H 10 ]leu will minimize the discrepancy between FSR values calculated using E b or E i compared to [ 13 C 6 ]phe‐calculated FSR values using the corresponding E b or E i . To test our hypothesis, six healthy subjects received simultaneous infusions of the two stable‐isotope tracers following standard protocols. The [ 2 H 9 ]leu‐calculated FSR (%h ‐1 ) was 0.08±0.01 based on E b and 0.18±0.01 based on E i . The corresponding [ 13 C 6 ]phe‐calculated FSR values were 0.06±0.01 and 0.25±0.02, respectively. Moreover, the difference in the [ 2 H 9 ]leu‐calculated FSR values using E i vs E b was significantly less ( P <0.01; 0.10±0.01) compared to the difference in the corresponding [ 13 C 6 ]phe‐calculated FSR values (0.19±0.02). We conclude that, compared to [ 13 C 6 ]phe, the [ 2 H 10 ]leu tracer offers a more accurate approach to calculating FSR when E b is sought as an alternative to the E i. Grant Funding Source : Supported by NIH/NIDDK Grant# R01 DK094062; NCATS Grant# UL1 TR000135
Hyperaminoacidemia eliminates the influence of body fat and insulin sensitivity on fractional synthesis rate and myostatin regulation in humans (1168.3)
Multiple conditions are linked to perturbed skeletal muscle protein (SMP) metabolism, including excess adiposity and insulin resistance. Here we delineate the precise roles of body fat and insulin sensitivity on SMP metabolism, and test the hypothesis that hyperaminoacidemia can eliminate the influence of these factors. Six healthy individuals underwent a DEXA scan to determine percent body fat (%BF; 16.3‐29.4%) and an oral glucose tolerance test (OGTT) to evaluate insulin sensitivity via Matsuda index (MI; 1.21‐12.0). Subjects received a primed, continuous infusion of L‐[2,3,3,4,5,5,5,6,6,6‐ 2 H 10 ]leucine to determine SMP fractional synthesis rate (FSR) in biopsies from the vastus lateralis . Myostatin (MSTN) mRNA, a marker of muscle wasting, was quantified in similar biopsies, and MSTN activation was assessed in plasma as the percent of active over latent protein. To evaluate the effect of hyperaminoacidemia, samples were collected before and during infusions of high amino acids (AA). In our subjects, %BF was not correlated with MI ( P =0.11). The %BF was only associated with MSTN mRNA ( P =0.02; r=0.81). However, MI was a key determinant in FSR ( P =0.02; r=0.83) and MSTN activation ( P <0.01; r=‐0.94). AA infusion eliminated all discrepancies in FSR and MSTN quantitations. Thus, SMP metabolism is more strongly linked to insulin sensitivity than body fat, but the influence is attenuated with hyperaminoacidemia. Grant Funding Source : Supported by NIH/NIDDK Grant# R01 DK094062; NCATS Grant# UL1 TR000135
Mineralization of breast capsular tissue: changes in factors affecting apatite formation and growth
Experiments were designed to investigate isolatable factors that could either promote or inhibit formation of hydroxyapatite (HA) crystals associated with mineralization of the fibrous capsule surrounding silicone breast implants. Explanted capsular tissue was minced, filtered (0.2μm), inoculated into culture plates containing DMEM/10% FBS and kept at 37°C, 95%O 2 . Within 14 days, biofilm‐like and suspending (planktonic) aggregates containing HA formed to a greater extent in plates inoculated with sample from calcified (CC) than non‐calcified (NC) capsules (158 vs 4 nephelometric turbidity units, respectively). Confocal microscopy of formalin‐fixed sections of NC showed the major cell types to be macrophages and fibroblasts. These cells were immunopositive for fetuin, a blood protein. In contrast, CC were largely fibrous; fetuin labeling was sparse except for the calcific plaque itself on the surface of the capsule adjacent to the implant. Thus, a factor which affects HA formation, possibly a HA nucleator, or a modifier of nucleator activity, can be isolated from mineralized fibrous breast capsules. Localization of fetuin within NC but not CC cells is consistent with its known role in inhibiting HA crystal growth. Supported by grants from the Fetzer Foundation, NIH HL88988 and Division of Experimental Surgery, Mayo Clinic.
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
Since its emergence at the end of 2019, SARS-CoV-2, the causative agent of COVID-19, has caused over 100 million infections and 2.4 million deaths worldwide. Recently, countries have begun administering approved COVID-19 vaccines, which elicit strong immune responses and prevent disease in most vaccinated individuals.
Occupational Pesticide Use and Risk of Non-Hodgkin Lymphoma
Radiofrequency ablation for palliative treatment of osseous metastases results in rapid, significant, and durable improvements in pain relief and quality of life: Results from the OPuS One trial.
12086 Background: Patients with bone metastases may experience pain and decreased quality of life. Standard of care therapies such as radiation therapy could take weeks for pain relief and carry a risk of radiation induced fracture. Minimally invasive percutaneous radiofrequency ablation (RFA) have been shown in small observational studies to be an alternative treatment for bone metastases. We report the results of the OPuS One trial evaluating RFA for the palliative treatment of patients with painful bone metastases. Methods: OPuS One (NCT03249584) was a multicenter prospective trial. 218 subjects with painful bone metastases (≥ 4/10 worst pain scores, Brief Pain Inventory [BPI], at target treated site) were enrolled from 15 sites. RFA was performed under image guidance at one or two locations. Vertebral augmentation was followed based on physician’s discretion. Subjects’ pain (BPI) and quality of life (EQ-5D) scores were calculated in subjects at three days, one week, and one, three, six, and 12 months post RFA. Rate of complete (0 pain score at treated site with no concomitant analgesic increase) and partial responders (≥ 2 pain score reduction without analgesic increase or analgesic reduction of ≥ 25% from baseline) were calculated. Device-, procedure-, and/or therapy-related adverse events (AEs) were collected. Results: 206 subjects, 113 (55%) female and 93 (45%) males (mean age was 63.7 years) were treated with RFA. Most common primary cancers were breast (23%), lung (23%), and kidney (10%). 184 (89%) subjects were treated for metastatic lesions involving the thoracolumbar spine and 22 (11%) subjects were treated for iliac crest, periacetabulum, sacrum or mixed vertebral and pelvic location. 99% (262/264) of RFA procedures were technically successful and 97% were followed by vertebral augmentation. Subjects reported significant improvement in worst pain from baseline at 7.8 to 5.5, 4.7, 3.6, 3.2, 2.4, and 2.6 at three days, one week and one, three, six, and 12 months post RFA, respectively (p < 0.0001 for all visits). Significant improvements were also seen in average pain (p < 0.0001 for all visits), pain interference (p < 0.0001 for all visits), and quality of life scores (p < 0.0001 for all visits). Overall response rates were 53%, 58%, 61%, 63%, 70%, and 75% at three days, one week, one month, three months, six months, and twelve months post RFA, respectively. Six AEs were reported with three as serious: intra-abdominal fluid collection, pneumonia and respiratory failure. 82 deaths were reported during the study, none were related to the device, therapy, and/or procedure. No skeletal related events were reported. Conclusions: In a large prospective multicenter trial, OPuS One, RFA provided rapid, significant, and durable improvements in pain relief and quality of life up to 12 months. Clinical trial information: NCT03249584.
Gender Distribution and Rates of Publication of Abstracts Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery Meeting Over a 25-Year Period
AbstractHigh‐grade gliomas (HGGs) are aggressive, treatment‐resistant, and often fatal human brain cancers. The TNF‐like weak inducer of apoptosis (TWEAK)/fibroblast growth factor‐inducible 14 (Fn14) signaling axis is involved in tissue repair after injury and constitutive signaling has been implicated in the pathogenesis of numerous solid cancers. The Fn14 gene is expressed at low levels in the normal, uninjured brain but is highly expressed in primary isocitrate dehydrogenase wild‐type and recurrent HGGs. Fn14 signaling is implicated in numerous aspects of glioma biology including brain invasion and chemotherapy resistance, but whether Fn14 overexpression can directly promote tumor malignancy has not been reported. Here, we used the replication‐competent avian sarcoma‐leukosis virus/tumor virus A system to examine the impact of Fn14 expression on glioma development and pathobiology. We found that the sole addition of Fn14 to an established oncogenic cocktail previously shown to generate proneural‐like gliomas led to the development of highly invasive and lethal brain cancer with striking biological features including extensive pseudopalisading necrosis, constitutive canonical and noncanonical NF‐κB pathway signaling, and high plasminogen activator inhibitor‐1 (PAI‐1) expression. Analyses of HGG patient datasets revealed that high human PAI‐1 gene (SERPINE1) expression correlates with shorter patient survival, and that the SERPINE1 and Fn14 (TNFRSF12A) genes are frequently co‐expressed in bulk tumor tissues, in tumor subregions, and in malignant cells residing in the tumor microenvironment. These findings provide new insights into the potential importance of Fn14 in human HGG pathobiology and designate both the NF‐κB signaling node and PAI‐1 as potential targets for therapeutic intervention.Main PointsThis work demonstrates that elevated levels of the TWEAK receptor Fn14 in tumor‐initiating, neural progenitor cells leads to the transformation of proneural‐like gliomas into more aggressive and lethal tumors that exhibit constitutive NF‐κB pathway activation and plasminogen activator inhibitor‐1 overexpression.